P. Golovics, M. Mandel, B. Lovasz, and P. Lakatos, Inflammatory bowel disease course in Crohn???s disease: Is the natural history changing?, World Journal of Gastroenterology, vol.20, issue.12, pp.3198-207, 2014.
DOI : 10.3748/wjg.v20.i12.3198

L. Beaugerie, Maladie de Crohn et rectocolite hémorragique, Paris: Medi-text éd, 2005.

E. Kim and D. Chang, Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis, World Journal of Gastroenterology, vol.20, issue.29, pp.9872-81, 2014.
DOI : 10.3748/wjg.v20.i29.9872

L. Peyrin-biroulet, A. Cieza, W. Sandborn, M. Coenen, Y. Chowers et al., Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health, Gut, vol.61, issue.2, pp.241-248, 2012.
DOI : 10.1136/gutjnl-2011-300049

URL : https://hal.archives-ouvertes.fr/hal-00683372

E. Louis and P. Marteau, Maladies inflammatoires chroniques de l'intestin. Rueil- Malmaison: Doin, 2009.

L. Beaugerie, G. Schénowitz, G. Tucat, and P. Marteau, Prise en charge des MICI, Montrouge: J. Libbey Eurotext, 2003.

D. Saussure, P. Bouhnik, and Y. , Maladie de Crohn de l'adulte. EMC -Gastro-Entérologie, janv, vol.2, issue.3, pp.1-18, 2007.

Y. Zhang and Y. Li, Inflammatory bowel disease: Pathogenesis, World Journal of Gastroenterology, vol.20, issue.1, pp.91-100, 2014.
DOI : 10.3748/wjg.v20.i1.91

A. Ananthakrishnan, Environmental Risk Factors for Inflammatory Bowel Diseases: A Review, Digestive Diseases and Sciences, vol.141, issue.Suppl 2, pp.367-74, 2013.
DOI : 10.1007/s10620-014-3350-9

. Rambaud-c, Traité de gastro-entérologie. Paris: Médecine-sciences Flammarion, 2005.

A. Ponder and M. Long, A clinical review of recent findings in the epidemiology of inflammatory bowel disease, Clin Epidemiol, vol.5, pp.237-284, 2013.

J. Calop, S. Limat, and C. Fernandez, Association nationale des enseignants de pharmacie clinique. Pharmacie clinique et thérapeutique, 2008.

J. Rambaud, Les maladies inflammatoires chroniques de l'intestin. ohn Libbey Eurotext, 1999.

F. Veloso, Extraintestinal manifestations of inflammatory bowel disease: Do they influence treatment and outcome?, World Journal of Gastroenterology, vol.17, issue.22, pp.2702-2709, 2011.
DOI : 10.3748/wjg.v17.i22.2702

S. Larsen, K. Bendtzen, and O. Nielsen, Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management, Annals of Medicine, vol.9, issue.7, pp.97-114, 2010.
DOI : 10.2165/00002018-200023050-00006

L. Chiche, T. Pham, and N. Schleinitz, Les manifestations articulaires associées aux maladies inflammatoires chroniques de l'intestin. Hépato-Gastro Oncol Dig. 1 mars, pp.36-42, 2011.

O. Roux and Y. Bouhnik, Manifestations extradigestives des maladies inflammatoires chroniques intestinales, AKOS, 2013.

L. Chiche, T. Pham, and N. Schleinitz, Les manifestations articulaires associées aux maladies inflammatoires chroniques de l'intestin. Hépato-Gastro Oncol Dig. 1 mars, pp.36-42, 2011.

M. Lemann, J. Bonnet, M. Allez, J. Gornet, and M. X. , L??sions ost??o-articulaires au cours des maladies inflammatoires chroniques de l???intestin, Gastroent??rologie Clinique et Biologique, vol.28, issue.5, pp.75-82, 2004.
DOI : 10.1016/S0399-8320(04)94991-3

K. Rothfuss, E. Stange, and K. Herrlinger, Extraintestinal manifestations and complications in inflammatory bowel diseases, World J Gastroenterol WJG. 14 août, vol.12, issue.30, pp.4819-4850, 2006.

G. Cadiot and . Gastro-entérologie, Paris: Ellipses, 2005.

J. Chevaux and P. Bulois, Management of intestinal strictures in inflammatory bowel disease, Acta Endoscopica, vol.6, issue.3, pp.129-162, 2013.
DOI : 10.1007/s10190-013-0316-2

M. Piquet and X. Hébuterne, Nutrition en pathologie digestive, 2007.

X. Hebuterne, A. , and R. , Conséquences nutritionnelles des maladies inflammatoires cryptogénétiques de l'intestin. Hépato-Gastro, pp.123-157, 2005.

J. Dyson and M. Rutter, Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk?, World Journal of Gastroenterology, vol.18, issue.29, pp.3839-3887, 2012.
DOI : 10.3748/wjg.v18.i29.3839

A. Moniuszko, A. Isniewska, and G. Rydzewska, Biomarkers in management of inflammatory bowel disease, Gastroenterology Review, vol.5, issue.5, pp.275-83, 2013.
DOI : 10.5114/pg.2013.38728

M. Papp, G. Norman, I. Altorjay, and P. Lakatos, Utility of serological markers in inflammatory bowel diseases: Gadget or magic?, World Journal of Gastroenterology, vol.13, issue.14, pp.2028-2064, 2007.
DOI : 10.3748/wjg.v13.i14.2028

L. Marthey, V. Laurent, O. De-boissieu, and F. Carbonnel, Actualité du diagnostic des MICI. [cité 3 sept 2014]; Disponible sur

R. Panaccione and S. Ghosh, Review: Optimal use of biologics in the management of Crohn???s disease, Therapeutic Advances in Gastroenterology, vol.354, issue.2, pp.179-89, 2010.
DOI : 10.1177/1756283X09357579

L. Peyrin-biroulet and C. De-nancy, Quand débuter un traitement anti-TNF? 2014 [cité 6 sept 2014]; Disponible sur

. Accueil-ansm, Agence nationale de sécurité du médicament et des produits de santé

J. Jouzeau, M. Daouphars, A. Benani, and P. Netter, Pharmacologie et classification des inhibiteurs de la cyclooxyg??nase, Gastroent??rologie Clinique et Biologique, vol.28, issue.3, pp.7-17, 2004.
DOI : 10.1016/S0399-8320(04)95274-8

M. Bardou and A. Barkun, Pr??vention des complications digestives des anti-inflammatoires non st??ro??diens??: de la connaissance des facteurs de risque ?? leur prise en compte, Revue du Rhumatisme, vol.77, issue.1, pp.7-13, 2010.
DOI : 10.1016/j.rhum.2009.04.008

. Afssaps, Analyse des ventes de médicaments aux officines et aux hôpitaux en France de 1998 à 2008 -rapport Afssaps, 2010.

S. Faure, Les anti-inflammatoires non st??ro??diens, Actualit??s Pharmaceutiques, vol.48, issue.489, pp.53-59, 2009.
DOI : 10.1016/S0515-3700(09)70516-6

M. Pirmohamed, S. James, S. Meakin, C. Green, A. Scott et al., Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, BMJ, vol.329, issue.7456, pp.15-24, 2004.
DOI : 10.1136/bmj.329.7456.15

H. Harizi, J. Corcuff, and N. Gualde, Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology, Trends in Molecular Medicine, vol.14, issue.10, pp.461-470, 2008.
DOI : 10.1016/j.molmed.2008.08.005

B. Katzung, Pharmacologie fondamentale et clinique, 2006.

S. Bacchi, P. Palumbo, A. Sponta, and M. Coppolino, Clinical pharmacology of nonsteroidal anti-inflammatory drugs: a review. Anti-Inflamm Anti, Allergy Agents Med Chem, vol.11, issue.1, pp.52-64, 2012.

P. Tréchot and J. Jouzeau, Bases chimiques et pharmacologiques des AINS, Revue Fran??aise d'Allergologie, vol.54, issue.3, pp.212-219, 2014.
DOI : 10.1016/j.reval.2014.01.026

F. Horn and . Biochimie-humaine, Paris: Flammarion médecine-sciences, 2005.

A. Randoux and . Biochimie-dynamique, De Boeck Supérieur, 1997.

K. Park and A. Bavry, Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag, janv, vol.10, issue.6, pp.25-32, 2014.

F. Pillon, Les anti-inflammatoires non st??ro??diens, Actualit??s Pharmaceutiques, vol.53, issue.534, pp.43-49, 2014.
DOI : 10.1016/j.actpha.2014.01.009

M. Talbert, G. Willoquet, and R. Gervais, GPC 2013: guide pharmaco clinique. [Rueil- Malmaison]: le Moniteur des pharmacies, 2013.

V. Michel and . Médicaments, Wolters Kluwer France, p.91, 2007.

B. Caulin, Guide du bon usage du médicament

. Lettre-aux-professionnels-de-santé, Information transmise par l'ANSM. Diclofénac par voie systémique -nouvelles contre-indications et mises en garde après une revue européenne de son profil de sécurité cardiovasculaire, 2013.

B. Bannwarth, Traitements anti-inflammatoires. Place des AINS classiques et des coxibs, EMC - M??decine, vol.2, issue.5, pp.524-555, 2005.
DOI : 10.1016/j.emcmed.2005.08.004

L. Beaugerie and G. Thiéfin, Complications intestinales li??es aux AINS, Gastroent??rologie Clinique et Biologique, vol.28, pp.62-72, 2004.
DOI : 10.1016/S0399-8320(04)95280-3

M. Bigard and A. Pelletier, Complications ??sophagiennes des m??dicaments anti-inflammatoires non st??ro??diens, Gastroent??rologie Clinique et Biologique, vol.28, issue.3, pp.58-61, 2004.
DOI : 10.1016/S0399-8320(04)95279-7

G. Thiéfin, Toxicit?? gastroduod??nale des m??dicaments anti-inflammatoires non st??ro??diens, EMC - Gastro-ent??rologie, vol.1, issue.1, p.11, 2003.
DOI : 10.1016/S1155-1968(03)00070-1

J. Wallace, NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies, British Journal of Pharmacology, vol.298, issue.1, pp.67-74, 2012.
DOI : 10.1111/j.1476-5381.2011.01509.x

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252967

D. Lamarque, Physiopathologie des l??sions gastro-duod??nales induites par les anti-inflammatoires non st??ro??diens, Gastroent??rologie Clinique et Biologique, vol.28, pp.18-26, 2004.
DOI : 10.1016/S0399-8320(04)95275-X

M. Sinha, L. Gautam, P. Shukla, P. Kaur, S. Sharma et al., Current Perspectives in NSAID-Induced Gastropathy, Mediators of Inflammation, vol.44, issue.5, pp.1-11, 2013.
DOI : 10.1016/j.abb.2010.05.026

H. Matsui, O. Shimokawa, T. Kaneko, Y. Nagano, K. Rai et al., The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine, Journal of Clinical Biochemistry and Nutrition, vol.48, issue.2, pp.107-118, 2011.
DOI : 10.3164/jcbn.10-79

B. Cryer and M. Feldman, Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans, Gastroenterology, vol.117, issue.1, pp.17-25, 1999.
DOI : 10.1016/S0016-5085(99)70545-7

J. Sibilia, P. Ravaud, and G. Marck, Digestive and hemorrhage complications of low-dose aspirin]. Presse Médicale Paris Fr 1983, 22 nov, vol.32, pp.17-28, 2003.

G. Singh, Recent considerations in nonsteroidal anti-inflammatory drug gastropathy, The American Journal of Medicine, vol.105, issue.1, pp.31-38, 1998.
DOI : 10.1016/S0002-9343(98)00072-2

L. Maiden, B. Thjodleifsson, A. Theodors, J. Gonzalez, and I. Bjarnason, A Quantitative Analysis of NSAID-Induced Small Bowel Pathology by Capsule Enteroscopy, Gastroenterology, vol.128, issue.5, pp.1172-1180, 2005.
DOI : 10.1053/j.gastro.2005.03.020

O. Handa, Y. Naito, A. Fukui, T. Omatsu, and T. Yoshikawa, The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium, Journal of Clinical Biochemistry and Nutrition, vol.54, issue.1, pp.2-6, 2014.
DOI : 10.3164/jcbn.13-84

J. Wallace, Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy, World Journal of Gastroenterology, vol.19, issue.12, pp.1861-76, 2013.
DOI : 10.3748/wjg.v19.i12.1861

U. Boelsterli, M. Redinbo, and K. Saitta, Multiple NSAID-Induced Hits Injure the Small Intestine: Underlying Mechanisms and Novel Strategies, Toxicological Sciences, vol.131, issue.2, pp.654-67, 2013.
DOI : 10.1093/toxsci/kfs310

I. Bjarnason, B. Fehilly, P. Smethurst, I. Menzies, and A. Levi, Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man., Gut, vol.32, issue.3, pp.275-282, 1991.
DOI : 10.1136/gut.32.3.275

Y. Zhou, E. Dial, R. Doyen, and L. Lichtenberger, Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs, AJP: Gastrointestinal and Liver Physiology, vol.298, issue.5, pp.722-753, 2010.
DOI : 10.1152/ajpgi.00387.2009

G. Thiéfin and A. Toxicité-intestinale-des, Disponible sur: https://www.fmcgastro.org/wp-content, 2014.

M. Petruzzelli, M. Vacca, A. Moschetta, C. Sasso, R. Palasciano et al., Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: Role of bile salts, Clinical Biochemistry, vol.40, issue.8, pp.503-513, 2007.
DOI : 10.1016/j.clinbiochem.2007.01.015

H. Kefalakes, T. Stylianides, G. Amanakis, and G. Kolios, Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?, European Journal of Clinical Pharmacology, vol.104, issue.5, pp.963-70, 2009.
DOI : 10.1007/s00228-009-0719-3

URL : https://hal.archives-ouvertes.fr/hal-00534990

C. Sostres, C. Gargallo, and A. Lanas, Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage, Arthritis Research & Therapy, vol.15, issue.Suppl 3, p.3, 2013.
DOI : 10.1186/ar4175

URL : http://doi.org/10.1186/ar4175

E. Cabré and E. Domènech, Impact of environmental and dietary factors on the course of inflammatory bowel disease, World Journal of Gastroenterology, vol.18, issue.29, pp.3814-3836, 2012.
DOI : 10.3748/wjg.v18.i29.3814

M. Neuman and R. Nanau, Inflammatory bowel disease: role of diet, microbiota, life style, Translational Research, vol.160, issue.1, pp.29-44, 2012.
DOI : 10.1016/j.trsl.2011.09.001

A. Berg, A. Dam, and F. Farraye, Environmental influences on the onset and clinical course of Crohn's disease-part 2: infections and medication use, Gastroenterol Hepatol. déc, vol.9, issue.12, pp.803-813, 2013.

A. Ananthakrishnan, Environmental Triggers for Inflammatory Bowel Disease, Current Gastroenterology Reports, vol.105, issue.Suppl 2, p.302, 2013.
DOI : 10.1007/s11894-012-0302-4

T. Nunes, G. Fiorino, S. Danese, and M. Sans, Familial aggregation in inflammatory bowel disease: Is it genes or environment?, World Journal of Gastroenterology, vol.17, issue.22, pp.2715-2737, 2011.
DOI : 10.3748/wjg.v17.i22.2715

D. Rampton and G. Sladen, Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs., Postgraduate Medical Journal, vol.57, issue.667, pp.297-306, 1981.
DOI : 10.1136/pgmj.57.667.297

H. Kaufmann and H. Taubin, Nonsteroidal Anti-Inflammatory Drugs Activate Quiescent Inflammatory Bowel Disease, Annals of Internal Medicine, vol.107, issue.4, pp.513-519, 1987.
DOI : 10.7326/0003-4819-107-4-513

A. Banerjee and T. Peters, Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors., Gut, vol.31, issue.12, pp.1358-64, 1990.
DOI : 10.1136/gut.31.12.1358

A. Banerjee, J. Marway, V. Preedy, and T. Peters, Studies of gut mucosal protein synthesis in a non-steroidal anti-inflammatory drug (NSAID) model of inflammatory bowel disease., Gut, vol.33, issue.2, pp.242-247, 1992.
DOI : 10.1136/gut.33.2.242

G. Bonner, Using COX-2 inhibitors in IBD: anti-inflammatories inflame a controversy, The American Journal of Gastroenterology, vol.43, issue.4, pp.783-788, 2002.
DOI : 10.1016/S0002-9270(98)00469-9

M. Guslandi, Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: Fact or fiction, World Journal of Gastroenterology, vol.12, issue.10, pp.1509-1519, 2006.
DOI : 10.3748/wjg.v12.i10.1509

J. Korzenik and D. Podolsky, Selective use of selective nonsteroidal antiinflammatory drugs in inflammatory bowel disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. févr, vol.4, issue.2, pp.157-166, 2006.

M. Docherty, R. Jones, and M. Wallace, Managing Pain in Inflammatory Bowel Disease, Gastroenterol Hepatol. sept, vol.7, issue.9, pp.592-601, 2011.

A. Srinath, C. Walter, M. Newara, and E. Szigethy, Pain management in patients with inflammatory bowel disease: insights for the clinician, Therapeutic Advances in Gastroenterology, vol.5, issue.5, pp.339-57, 2012.
DOI : 10.1177/1756283X12446158

J. Felder, B. Korelitz, R. Rajapakse, S. Schwarz, A. Horatagis et al., Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study, The American Journal of Gastroenterology, vol.41, issue.8, pp.1949-54, 2000.
DOI : 10.1016/S0140-6736(84)92739-9

G. Bonner, M. Walczak, L. Kitchen, and M. Bayona, Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease, The American Journal of Gastroenterology, vol.115, issue.8, 2000.
DOI : 10.1001/archinte.152.3.625

U. Mahadevan, E. Loftus, W. Tremaine, and W. Sandborn, Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease, The American Journal of Gastroenterology, vol.157, issue.5, pp.910-914, 2002.
DOI : 10.1056/NEJM200006293422603

W. Reinisch, W. Miehsler, C. Dejaco, M. Harrer, T. Waldhoer et al., An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia, Alimentary Pharmacology and Therapeutics, vol.115, issue.11, pp.1371-80, 2003.
DOI : 10.1111/j.1572-0241.2002.07142.x

G. Bonner, Exacerbation of inflammatory bowel disease associated with use of celecoxib, The American Journal of Gastroenterology, vol.115, issue.4, pp.1306-1314, 2001.
DOI : 10.1056/NEJM199406303302601

A. Ananthakrishnan, L. Higuchi, E. Huang, H. Khalili, J. Richter et al., Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis, Annals of Internal Medicine, vol.156, issue.5, pp.350-359, 2012.
DOI : 10.7326/0003-4819-156-5-201203060-00007

S. Chan, R. Luben, M. Bergmann, H. Boeing, A. Olsen et al., Aspirin in the aetiology of Crohn???s disease and ulcerative colitis: a European prospective cohort study, Alimentary Pharmacology & Therapeutics, vol.125, issue.Suppl., pp.649-55, 2011.
DOI : 10.1111/j.1365-2036.2011.04784.x

K. Takeuchi, S. Smale, P. Premchand, L. Maiden, R. Sherwood et al., Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug???Induced Clinical Relapse in Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.196-202, 2006.
DOI : 10.1016/S1542-3565(05)00980-8

A. Meyer, N. Ramzan, R. Heigh, and J. Leighton, Relapse of Inflammatory Bowel Disease Associated With Use of Nonsteroidal Anti-Inflammatory Drugs, Digestive Diseases and Sciences, vol.92, issue.1, pp.168-72, 2006.
DOI : 10.1007/s10620-006-3103-5

G. Bonner, A. Fakhri, and S. Vennamaneni, A Long-term Cohort Study of Nonsteroidal Anti-inflammatory Drug Use and Disease Activity in Outpatients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.6, pp.751-758, 2004.
DOI : 10.1097/00054725-200411000-00009

E. Miedany, Y. Youssef, S. Ahmed, I. , E. Gaafary et al., The Gastrointestinal Safety and Effect on Disease Activity of Etoricoxib, a Selective Cox-2 Inhibitor in Inflammatory Bowel Diseases, The American Journal of Gastroenterology, vol.4, issue.4, pp.311-318, 2006.
DOI : 10.1056/NEJMoa021907

W. Sandborn, W. Stenson, J. Brynskov, R. Lorenz, G. Steidle et al., Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.203-214, 2006.
DOI : 10.1016/j.cgh.2005.12.002

L. Biancone, C. Tosti, A. Geremia, D. Fina, C. Petruzziello et al., Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial, Alimentary Pharmacology and Therapeutics, vol.122, issue.3, pp.755-64, 2004.
DOI : 10.1056/NEJM200011233432103

R. Matuk, J. Crawford, M. Abreu, S. Targan, E. Vasiliauskas et al., The Spectrum of Gastrointestinal Toxicity and Effect on Disease Activity of Selective Cyclooxygenase-2 Inhibitors in Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.4, pp.352-358, 2004.
DOI : 10.1097/00054725-200407000-00005

J. Evans, A. Mcmahon, F. Murray, D. Mcdevitt, and T. Macdonald, Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease., Gut, vol.40, issue.5, pp.619-641, 1997.
DOI : 10.1136/gut.40.5.619

X. Miao, Q. Ouyang, H. Li, Z. Wen, D. Zhang et al., Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis, Current Therapeutic Research, vol.69, issue.3, pp.181-91, 2008.
DOI : 10.1016/j.curtheres.2008.06.009

S. Singh, L. Graff, and C. Bernstein, Do NSAIDs, Antibiotics, Infections, or Stress Trigger Flares in IBD?, The American Journal of Gastroenterology, vol.89, issue.5, pp.1298-313, 2009.
DOI : 10.1037/0278-6133.21.6.531

L. Feagins and B. Cryer, Do Non-steroidal Anti-inflammatory Drugs Cause Exacerbations of Inflammatory Bowel Disease?, Digestive Diseases and Sciences, vol.31, issue.2, pp.226-258, 2010.
DOI : 10.1007/s10620-009-1042-7

A. Klein and R. Eliakim, Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease, Pharmaceuticals, vol.3, issue.4, pp.1084-92, 2010.
DOI : 10.3390/ph3041084

C. Cretton, Comment permettre aux patients de d??crypter l???information sur Internet??? Construction d???un outil d?????valuation des sites d???information sant?? ?? destination des patients, Le Pharmacien Hospitalier et Clinicien, vol.49, issue.2
DOI : 10.1016/j.phclin.2014.04.330